 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Postmenopausal Hormone Therapy and Blood Sugar
7 January 2003 | Volume 138 Issue 1 | Page I-10
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
The summary below is from the full report titled "Glycemic Effects of Postmenopausal Hormone Therapy: The Heart and Estrogen/progestin Replacement Study. A Randomized, Double-Blind, Placebo-Controlled Trial." It is in the 7 January 2003 issue of Annals of Internal Medicine (volume 138, pages 1-9). The authors are AM Kanaya, D Herrington, E Vittinghoff, F Lin, D Grady, V Bittner, JA Cauley, and E Barrett-Connor.
What is the problem and what is known about it so far?
After menopause, the ovaries stop making the hormones estrogen and progesterone. For some women, the decrease in hormone levels causes hot flashes and other uncomfortable symptoms. Postmenopausal hormone therapy consists of taking estrogen with or without progesterone to reduce the uncomfortable symptoms of menopause. A recent study showed that postmenopausal hormone therapy also reduces colorectal cancer and osteoporosis but increases heart attack, stroke, and breast cancer. Ongoing studies are examining other risks and benefits of hormone therapy. Some previous studies suggest that women taking hormone replacement therapy have better blood sugar levels than women not taking it. Blood sugar is important in postmenopausal women because of its relationship to type 2 diabetes. Type 2 diabetes is a common disease that interferes with the body's ability to use and store energy from food and leads to high blood sugar levels. Over time, high blood sugar levels can lead to blindness, kidney failure, nerve damage, and possibly heart disease.
Why did the researchers do this particular study?
To see whether postmenopausal hormone therapy reduces blood sugar levels and incidence of type 2 diabetes.
Who was studied?
2763 women with heart disease who were participating in a study of hormone therapy and heart disease.
How was the study done?
The researchers assigned the study participants to take either hormone therapy or placebo pills that looked exactly like the hormones but contained no active ingredients. The researchers measured fasting blood sugar levels in women at the start of the study, after 1 year, and at the end of the study (an average of 4 years for most women). They compared the numbers of women who developed high blood sugar levels or diabetes in each of the groups. The researchers excluded women who already had diabetes or high blood sugar levels at the beginning of the study.
What did the researchers find?
Blood sugar levels increased in the women taking placebo but did not change in the women taking hormone therapy. Of the women taking hormones, 6.2% developed diabetes compared with 9.5% taking placebo. The researchers estimated that one case of diabetes could be prevented for every 30 women who take hormone replacement therapy for 4 years.
What were the limitations of the study?
The women in this study all had heart disease, and the hormones prescribed were 0.625 mg of conjugated estrogen plus 2.5 mg of medroxyprogesterone acetate. The results might not apply to women without heart disease or to those taking other hormone preparations.
What are the implications of the study?
The decision about whether to take postmenopausal hormone therapy depends on each woman's personal preferences and risks. This study suggests that preventing diabetes might be one of the few benefits of postmenopausal hormone therapy.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  M. J. Toth, B. C. Cooper, R. E. Pratley, A. Mari, D. E. Matthews, and P. R. Casson Effect of ovarian suppression with gonadotropin-releasing hormone agonist on glucose disposal and insulin secretion Am J Physiol Endocrinol Metab, June 1, 2008; 294(6): E1035 - E1045. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rees, J. Stevenson, and on behalf of the British Menopause Society Council Primary prevention of coronary heart disease in women Menopause Int, March 1, 2008; 14(1): 40 - 45. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Van Pelt, R. S. Schwartz, and W. M. Kohrt Insulin Secretion and Clearance after Subacute Estradiol Administration in Postmenopausal Women J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 484 - 490. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Karim, H. N. Hodis, F. Z. Stanczyk, R. A. Lobo, and W. J. Mack Relationship between Serum Levels of Sex Hormones and Progression of Subclinical Atherosclerosis in Postmenopausal Women J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 131 - 138. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Boyd, C. Boult, E. Shadmi, B. Leff, R. Brager, L. Dunbar, J. L. Wolff, and S. Wegener Guided Care for Multimorbid Older Adults: Kathleen Walsh Piercy, PhD, Editor Gerontologist, October 1, 2007; 47(5): 697 - 704. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. M. Wasko, H. B. Hubert, V. B. Lingala, J. R. Elliott, M. E. Luggen, J. F. Fries, and M. M. Ward Hydroxychloroquine and Risk of Diabetes in Patients With Rheumatoid Arthritis JAMA, July 11, 2007; 298(2): 187 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. V. d. Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur. Heart J. Suppl., June 1, 2007; 9(suppl_C): C3 - C74. [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Wierman and W. M. Kohrt Review Article: Vascular and Metabolic Effects of Sex Steroids: New Insights Into Clinical Trials Reproductive Sciences, May 1, 2007; 14(4): 300 - 314. [Abstract] [PDF]
|
|
|
|
|
|
S. H. Golden, A. S. Dobs, D. Vaidya, M. Szklo, S. Gapstur, P. Kopp, K. Liu, and P. Ouyang Endogenous Sex Hormones and Glucose Tolerance Status in Postmenopausal Women J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1289 - 1295. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Miyazaki-Akita, T. Hayashi, Q. F. Ding, H. Shiraishi, T. Nomura, Y. Hattori, and A. Iguchi 17beta-Estradiol Antagonizes the Down-Regulation of Endothelial Nitric-Oxide Synthase and GTP Cyclohydrolase I by High Glucose: Relevance to Postmenopausal Diabetic Cardiovascular Disease J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 591 - 598. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. W. Mankhey, C. C. Wells, F. Bhatti, and C. Maric 17beta-Estradiol supplementation reduces tubulointerstitial fibrosis by increasing MMP activity in the diabetic kidney Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2007; 292(2): R769 - R777. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. Van den Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur. Heart J., January 1, 2007; 28(1): 88 - 136. [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. van Genugten, K. M. Utzschneider, J. Tong, F. Gerchman, S. Zraika, J. Udayasankar, E. J. Boyko, W. Y. Fujimoto, S. E. Kahn, and and the American Diabetes Association GENNID Study Effects of Sex and Hormone Replacement Therapy Use on the Prevalence of Isolated Impaired Fasting Glucose and Isolated Impaired Glucose Tolerance in Subjects With a Family History of Type 2 Diabetes Diabetes, December 1, 2006; 55(12): 3529 - 3535. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Le May, K. Chu, M. Hu, C. S. Ortega, E. R. Simpson, K. S. Korach, M.-J. Tsai, and F. Mauvais-Jarvis Estrogens protect pancreatic beta-cells from apoptosis and prevent insulin-deficient diabetes mellitus in mice PNAS, June 13, 2006; 103(24): 9232 - 9237. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Gao, G. Bryzgalova, E. Hedman, A. Khan, S. Efendic, J.-A. Gustafsson, and K. Dahlman-Wright Long-Term Administration of Estradiol Decreases Expression of Hepatic Lipogenic Genes and Improves Insulin Sensitivity in ob/ob Mice: A Possible Mechanism Is through Direct Regulation of Signal Transducer and Activator of Transcription 3 Mol. Endocrinol., June 1, 2006; 20(6): 1287 - 1299. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D.-J. Kim and E. Barrett-Connor Association of serum proinsulin with hormone replacement therapy in nondiabetic older women: the rancho bernardo study. Diabetes Care, March 1, 2006; 29(3): 618 - 624. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Burgener, P. Twigg, and A. Popovich Measuring psychological well-being in cognitively impaired persons Dementia, November 1, 2005; 4(4): 463 - 485. [Abstract] [PDF]
|
|
|
|
|
|
E. Selvin, J. Coresh, S. H. Golden, L. L. Boland, F. L. Brancati, and M. W. Steffes Glycemic Control, Atherosclerosis, and Risk Factors for Cardiovascular Disease in Individuals With Diabetes: The Atherosclerosis Risk in Communities study Diabetes Care, August 1, 2005; 28(8): 1965 - 1973. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Day, W. S. Gozansky, R. E. Van Pelt, R. S. Schwartz, and W. M. Kohrt Sex Hormone Suppression Reduces Resting Energy Expenditure and {beta}-Adrenergic Support of Resting Energy Expenditure J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3312 - 3317. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. K. Sites, G. D. L'Hommedieu, M. J. Toth, M. Brochu, B. C. Cooper, and P. A. Fairhurst The Effect of Hormone Replacement Therapy on Body Composition, Body Fat Distribution, and Insulin Sensitivity in Menopausal Women: A Randomized, Double-Blind, Placebo-Controlled Trial J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2701 - 2707. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Ostberg, M. J. H. Attar, V. Mohamed-Ali, and G. S. Conway Adipokine Dysregulation in Turner Syndrome: Comparison of Circulating Interleukin-6 and Leptin Concentrations with Measures of Adiposity and C-Reactive Protein J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2948 - 2953. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. B. Peterson, S. B. Thacker, P. S. Corso, P. A. Marchbanks, and J. P. Koplan Hormone Therapy: Making Decisions in the Face of Uncertainty Arch Intern Med, November 22, 2004; 164(21): 2308 - 2312. [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Skyler Effects of Glycemic Control on Diabetes Complications and on the Prevention of Diabetes Clin. Diabetes, October 1, 2004; 22(4): 162 - 166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. V. Howard, J. Hsia, P. Ouyang, L. Van Voorhees, J. Lindsay, A. Silverman, E. L. Alderman, M. Tripputi, and D. D. Waters Postmenopausal Hormone Therapy Is Associated With Atherosclerosis Progression in Women With Abnormal Glucose Tolerance Circulation, July 13, 2004; 110(2): 201 - 206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Prisant Preventing Type II Diabetes Mellitus J. Clin. Pharmacol., April 1, 2004; 44(4): 406 - 413. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. T. Chlebowski, J. Wactawski-Wende, C. Ritenbaugh, F. A. Hubbell, J. Ascensao, R. J. Rodabough, C. A. Rosenberg, V. M. Taylor, R. Harris, C. Chen, et al. Estrogen plus Progestin and Colorectal Cancer in Postmenopausal Women N. Engl. J. Med., March 4, 2004; 350(10): 991 - 1004. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Rossi, G. Origliani, and M. G. Modena Transdermal 17-{beta}-Estradiol and Risk of Developing Type 2 Diabetes in a Population of Healthy, Nonobese Postmenopausal Women Diabetes Care, March 1, 2004; 27(3): 645 - 649. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Malik JournalScan Heart, March 1, 2004; 90(3): 353 - 354. [Full Text] [PDF]
|
|
|
|
 |
|
 J. V.L. Sheffield and E. B. Larson Postmenopausal Hormones and Glycemic Effects Ann Intern Med, December 16, 2003; 139(12): 1043 - 1043. [Full Text] [PDF]
|
|
|
|
|
|
J. P. Girod and D. J. Brotman Postmenopausal Hormones and Glycemic Effects Ann Intern Med, December 16, 2003; 139(12): 1043 - 1043. [Full Text] [PDF]
|
|
|
|
|
|
A. McElduff Postmenopausal Hormones and Glycemic Effects Ann Intern Med, December 16, 2003; 139(12): 1043 - 1044. [Full Text] [PDF]
|
|
|
|
|
|
J. R. Greenfield, K. Samaras, A. B. Jenkins, P. J. Kelly, T. D. Spector, and L. V. Campbell Moderate Alcohol Consumption, Estrogen Replacement Therapy, and Physical Activity Are Associated With Increased Insulin Sensitivity: Is abdominal adiposity the mediator? Diabetes Care, October 1, 2003; 26(10): 2734 - 2740. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 ADDITIONAL ARTICLES ABSTRACTED IN ACP JOURNAL CLUB Evid. Based Med., September 1, 2003; 8(5): 131 - 131. [Full Text] [PDF]
|
|
|
|
|
|
R. E. Van Pelt, W. S. Gozansky, R. S. Schwartz, and W. M. Kohrt Intravenous estrogens increase insulin clearance and action in postmenopausal women Am J Physiol Endocrinol Metab, August 1, 2003; 285(2): E311 - E317. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 OTHER ARTICLES NOTED (24 Jan 03 to 18 Apr 03) Evid. Based Nurs., July 1, 2003; 6(3): e1 - 12. [Full Text] [PDF]
|
|
|
|
 |
|
 N.D. Stojanovic, P. Kwong, D.J. Byrne, A. Arnold, I.A. Jagroop, D. Nair, M. Press, S. Hurel, D.P. Mikhailidis, and G.M. Prelevic The Effects of Transdermal Estradiol Alone or with Cyclical Dydrogesterone on Markers of Cardiovascular Disease Risk in Postmenopausal Women with Type 2 Diabetes: A Pilot Study Angiology, July 1, 2003; 54(4): 391 - 399. [Abstract] [PDF]
|
|
|
|
 |
|
 G. Koerbel and M. Korytkowski Coronary Heart Disease in Women With Diabetes Diabetes Spectr, July 1, 2003; 16(3): 148 - 153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Greenspan, N. M. Resnick, and R. A. Parker Combination Therapy With Hormone Replacement and Alendronate for Prevention of Bone Loss in Elderly Women: A Randomized Controlled Trial JAMA, May 21, 2003; 289(19): 2525 - 2533. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Sattar, K. Williams, T. S. Han, C. Gonzalez-Villalpando, M. E.J. Lean, and S. M. Haffner Prospective Relation of C-Reactive Protein With Type 2 Diabetes: Response to Snijder et al. Diabetes Care, May 1, 2003; 26(5): 1657 - 1658. [Full Text] [PDF]
|
|
|
|
 |
|
 HRT for Diabetes Prevention? Journal Watch (General), January 24, 2003; 2003(124): 4 - 4. [Full Text]
|
|
|
|
 |
|
 Minerva BMJ, January 18, 2003; 326(7381): 172 - 172. [Full Text] [PDF]
|
|
|
|
|
|
P. W.F. Wilson Lower Diabetes Risk with Hormone Replacement Therapy: An Encore for Estrogen? Ann Intern Med, January 7, 2003; 138(1): 69 - 70. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
